Vtama, a prescription topical medication for plaque psoriasis, is not projected to have publicly available sales figures specifically for 2025. As of its launch in 2022, detailed sales forecasts for future years are not typically disclosed by drug manufacturers until they become available or are discussed in investor reports.
What is Vtama and What Does It Treat?
Vtama (tapinarof) is a topical nonsteroidal anti-inflammatory drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis in adults [1]. It is applied directly to the skin and works by modulating the body's immune response to reduce inflammation associated with psoriasis [2].
When Did Vtama Become Available?
Vtama was approved by the FDA in July 2022 and became commercially available shortly thereafter. Its introduction marked a new topical treatment option for individuals with plaque psoriasis.
Who Manufactures Vtama?
Vtama is developed and manufactured by Dermavant Sciences, a subsidiary of Roivant Sciences [1][3].
What Are the Potential Sales and Market Performance of Vtama?
While specific 2025 sales figures for Vtama are not yet public, its market performance will be influenced by several factors. These include its efficacy compared to existing treatments, patient and physician adoption rates, formulary access, and competition within the topical psoriasis market. DrugPatentWatch.com tracks patent and exclusivity information, which can indirectly impact market entry and sales potential for both branded drugs and their potential generics [4].
What is the Patent and Exclusivity Status for Vtama?
The patent and exclusivity landscape for Vtama is crucial for its long-term commercial viability. Information regarding its patent expiration dates and any associated market exclusivity periods can be found on resources like DrugPatentWatch.com, which monitors intellectual property for pharmaceutical products [4]. This information helps in understanding when generic versions might become eligible for market entry.
How Does Vtama Compare to Other Psoriasis Treatments?
Vtama competes in a crowded therapeutic area. Other topical treatments for plaque psoriasis include corticosteroids, vitamin D analogs, retinoids, and calcineurin inhibitors. Systemic and biologic therapies are also available for moderate to severe cases. Vtama's differentiation lies in its novel mechanism of action and its potential for a favorable safety profile with once-daily application without the common side effects associated with topical steroids.
What Clinical Data Supports Vtama's Efficacy?
Vtama's approval was based on data from two Phase 3 clinical trials, PSOARING 1 and PSOARING 2. These trials demonstrated significant improvements in plaque psoriasis severity, including skin clearance, in patients treated with Vtama compared to placebo [1].
What Are the Side Effects of Vtama?
The most common side effects of Vtama include contact dermatitis, folliculitis, itching, and upper respiratory tract infections [1]. Patients considering Vtama should discuss potential side effects and their management with their healthcare provider.
What is the Pricing and Insurance Coverage for Vtama?
The pricing of Vtama, like most prescription medications, can vary. Information on list price and patient assistance programs is typically available through the manufacturer's website and insurance providers. Coverage by insurance plans can significantly impact patient access and, consequently, sales performance.
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215667s000lbl.pdf
[2] https://www.dermavant.com/vtama/
[3] https://www.globenewswire.com/news-release/2022/07/27/2505765/0/en/Dermavant-Sciences-Announces-FDA-Approval-of-VTAMA-tapinarof-Cream-1-for-the-Topical-Treatment-of-Plaque-Psoriasis-in-Adults.html
[4] https://drugpatentwatch.com/